Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517 | 0.94 | SIGMAR1 (0.48) | IDO1LMNASIGMAR1FFAR1DRD2 | |
| SCHEMBL99522 | 0.93 | MEN1 (0.49) | IDO1LMNASIGMAR1SMN1; SMN2FFAR1 | |
| SCHEMBL5544962 | 0.93 | MEN1 (0.49) | IDO1LMNASIGMAR1SMN1; SMN2FFAR1 | |
| SCHEMBL97332 | 0.92 | SIGMAR1 (0.52) | IDO1SIGMAR1FFAR1 | |
| SCHEMBL96962 | 0.92 | SIGMAR1 (0.52) | IDO1SIGMAR1FFAR1 | |
| SCHEMBL5537364 | 0.91 | MEN1 (0.47) | IDO1LMNASIGMAR1 | |
| SCHEMBL5542421 | 0.91 | MEN1 (0.47) | IDO1LMNASIGMAR1 | |
| SCHEMBL5543316 | 0.89 | MEN1 (0.49) | IDO1LMNASIGMAR1SMN1; SMN2FFAR1 | |
| SCHEMBL5542777 | 0.89 | FFAR1 (0.46) | IDO1LMNAFFAR1HDAC1HDAC2 | |
| SCHEMBL97490 | 0.89 | TDP1 (0.46) | IDO1LMNASIGMAR1FFAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | claimed |
| CN-108514559-A | Oral liquid containing orlistat and calcium supplement organic acid calcium eutectic | 中山万汉制药有限公司 | 2018-09-11 | — | — | CN | claimed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | claimed |
| CN-106074560-A | The application of Fructus Rubi extract | 江西中医药大学 | 2016-11-09 | — | — | CN | claimed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | claimed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | claimed |
| CN-103405486-A | Chrysanthemum flower formula granules, and preparation method and quality control method thereof | ANHUI JIREN PHARMACEUTICAL CO LTD | 2013-11-27 | — | — | CN | claimed |
| CN-103405505-A | Mulberry bark formula granules, and preparation method and quality control method thereof | ANHUI JIREN PHARMACEUTICAL CO LTD | 2013-11-27 | — | — | CN | claimed |
| CN-1178912-C | Small molecule inhibitors of rotamase enzyme activity | ������˹ҩƷ��˾ | 2004-12-08 | — | — | CN | claimed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | claimed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | claimed |
| US-20040068122-A1 | Delta1-pyrrolines used as pesticides | BAYER CROPSCIENCE AG (DE) | 2004-04-08 | — | — | US | claimed |
| WO-2004013086-A1 | PHOTOACTIVE MATERIALS | ROLIC AG (CH) | 2004-02-12 | — | — | WO | claimed |
| EP-1386910-A1 | Photoactive materials | Rolic AG (CH) | 2004-02-04 | — | — | EP | claimed |
| EP-1322608-A1 | DELTA1-PYRROLINES USED AS PESTICIDES | Bayer CropScience AG (DE) | 2003-07-02 | — | — | EP | claimed |
| CN-1422851-A | Substituted five-membered nitrogen heterocyclic compound and application thereof in preventing and treating neurodegenerative diseases | TOXICANT AND MEDICINE INST MIL (CN) | 2003-06-11 | — | — | CN | claimed |
| WO-2002024646-A1 | DELTA1-PYRROLINES USED AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2002-03-28 | — | — | WO | claimed |
| CN-1187188-A | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARM INC (US) | 1998-07-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068122-A1 | Delta1-pyrrolines used as pesticides | DDT, ADRA1D, OPRD1 | IDO1 342/4885LMNA 3251/4885SIGMAR1 449/4885 |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | IDO1 239/4885LMNA 4840/4885SIGMAR1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.